| # | Company | Location | Employees | Total Funding | Last Round | Last Funded |
|---|---|---|---|---|---|---|
| 1 |
BillionToOne
BillionToOne is a precision diagnostics company that focuses on genetic testing …
|
Menlo Park | 501 - 1K | $425.9M | Series D | 2024-06-21 |
| 2 |
Parse Biosciences
Parse Biosciences is a biotechnology startup company that develops single-cell s…
|
Seattle | 101 - 250 | $100.0M | Series C | 2023-12-14 |
| 3 |
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company pioneering Gene Writing™ to driv…
|
Cambridge | 251 - 500 | $773.1M | Grant | 2026-03-23 |
| 4 |
Variant Bio
Variant Bio is leveraging the power of human genetic diversity to discover new t…
|
Seattle | 11 - 50 | $129.7M | Series B | 2021-11-09 |
| 5 |
enGene
enGene is a biotechnology company develops treatment for mucosal diseases throug…
|
Vancouver | 11 - 50 | $409.6M | Post Ipo Debt | 2026-01-20 |
| 6 |
Relation Therapeutics
Relation Therapeutics is a biotechnology company that focuses on humanizing drug…
|
London | 11 - 50 | $95.0M | Series Unknown | 2025-12-09 |
| 7 |
Colossal Biosciences
Colossal Biosciences is a biotechnology and genetic engineering company that use…
|
Austin | 101 - 250 | $628.1M | Series C | 2026-02-03 |
| 8 |
Oxford Nanopore Technologies
Oxford Nanopore Technologies is a biotechnology company that develops and commer…
|
Oxford | 1K - 5K | $1.6B | Post Ipo Equity | 2024-08-01 |
| 9 |
Element Biosciences
Element Biosciences is a life science company that focuses on developing innovat…
|
San Diego | 251 - 500 | $678.0M | Series D | 2024-07-11 |
| 10 |
Encoded Therapeutics
Encoded Therapeutics is a Harnessing the regulatory genome to create next-genera…
|
South San Francisco | 101 - 250 | $239.1M | Series D | 2021-03-15 |
| 11 |
SOPHiA GENETICS
SOPHiA GENETICS is a biotechnology firm that aims to support healthcare professi…
|
Boston | 251 - 500 | $265.2M | Post Ipo Debt | 2024-05-02 |
| 12 |
Helix
Helix is a population genomics company that is working to advance genomics resea…
|
San Mateo | 101 - 250 | $403.0M | Series C | 2021-06-03 |
| 13 |
Sweep
Sweep is a software company developing software for businesses to reduce their c…
|
Montpellier | 101 - 250 | $100.0M | Series B | 2022-04-04 |
| 14 |
Legacy
Legacy provides a service for at-home sperm testing and cryopreservation, allowi…
|
New York | 11 - 50 | $47.1M | Series Unknown | 2024-07-18 |
| 15 |
23andMe
23andMe is a DNA testing technology company that enables its users to access the…
|
Sunnyvale | 251 - 500 | $1.1B | Post Ipo Equity | 2021-06-17 |
| 16 |
BostonGene
BostonGene is a biomedical software company for advanced patient analysis and pe…
|
Waltham | 251 - 500 | $200.0M | Series B | 2022-04-06 |
| 17 |
Moderna
Moderna Therapeutics is a biotechnology company that specializes in vaccines and…
|
Cambridge | 1K - 5K | $4.6B | Grant | 2025-12-18 |
| 18 |
Natera
Natera specializes in cell-free DNA testing to provide a more targeted intervent…
|
San Carlos | 1K - 5K | $1.2B | Post Ipo Equity | 2023-09-07 |
| 19 |
Kelonia Therapeutics
Kelonia Therapeutics is developing a new wave of genetic medicines using its nex…
|
Boston | 11 - 50 | $50.0M | Series A | 2022-04-28 |
| 20 |
Mission Bio
Mission Bio develops only single-cell multi-omics platform integrating genotype …
|
San Francisco | 101 - 250 | $150.9M | Series Unknown | 2025-08-05 |
| 21 |
Deepcell
Deepcell is a life science company specializing in AI-powered single-cell classi…
|
Menlo Park | 101 - 250 | $98.0M | Series Unknown | 2025-04-24 |
| 22 |
Synthego
Synthego is a genome engineering company that enables access to CRISPR to accele…
|
Redwood City | 101 - 250 | $459.7M | Series E | 2022-02-17 |
| 23 |
Suzhou Ribo Life Science
Suzhou Ribo Life Science develops nucleic acid drugs and related products based …
|
Kunshan | 101 - 250 | $169.4M | Series E | 2025-07-21 |
| 24 |
Prime Medicine
Prime Medicine is a biotechnology company that utilizes Prime Editing to modify …
|
Cambridge | 101 - 250 | $558.1M | Post Ipo Equity | 2025-08-01 |
| 25 |
EGenesis
EGenesis is a gene editing and genome engineering company developing human-compa…
|
Cambridge | 101 - 250 | $456.0M | Series D | 2024-09-04 |
| 26 |
Gameto
Gameto is a biotechnology company developing therapeutics of the female reproduc…
|
New York | 11 - 50 | $117.0M | Series C | 2025-08-12 |
| 27 |
QurAlis
QurAlis is a biotechnology company that creates precision medicine solutions to …
|
Cambridge | 51 - 100 | $135.5M | Series B | 2023-03-09 |
| 28 |
Metavalis
Veteran led Strategic Bioengineering Firm Merging AI infrastructure with our pro…
|
Branson | 1 - 10 | $40K | Angel | 2026-04-05 |
| 29 |
OutSee
OutSee creates cutting-edge computational methods for genomics for the developme…
|
Cambridge | 1 - 10 | $3.4M | Seed | 2025-06-24 |
| 30 |
Pow.bio
Pow.bio provides a genetically engineered solution for fermentation scientists.
|
Berkeley | 11 - 50 | $11.4M | Series A | 2023-10-04 |
| 31 |
Maze Therapeutics
Maze Therapeutics is a biotechnology company that develops precision medicines f…
|
South San Francisco | 101 - 250 | $646.0M | Post Ipo Equity | 2025-09-11 |
| 32 |
Mainz Biomed
Mainz BioMed is a molecular genetic diagnostics company that develops market-rea…
|
Mainz | 51 - 100 | $95.5M | Post Ipo Equity | 2026-02-13 |
| 33 |
RheumaGen
RheumaGen develops a class of cell and gene therapy treatments aimed at autoimmu…
|
Aurora | 1 - 10 | $19.9M | Series A | 2025-12-22 |
| 34 |
ReCode Therapeutics
ReCode Therapeutics is a genetic medicines company that specializes in mRNA and …
|
Dallas | 11 - 50 | $386.4M | Debt Financing | 2025-09-29 |
| 35 |
L7 Informatics
L7 Informatics provides a unified platform, L7|ESP®, that contextualizes data an…
|
Austin | 101 - 250 | $62.1M | Series C | 2022-06-07 |
| 36 |
HAYA Therapeutics
HAYA Therapeutics is a biotechnology company developing precision RNA-guided med…
|
Lausanne | 11 - 50 | $1.1B | Grant | 2025-09-01 |
| 37 |
Gero
Gero is a biotechnology company that provides therapeutics against chronic disea…
|
Singapore | 11 - 50 | $18.7M | Undisclosed | 2024-01-08 |
| 38 |
SAGA Diagnostics
Liquid biopsy testing specialists. Ultrasensitive cancer diagnosis and monitorin…
|
Lund | 11 - 50 | $18.0M | Series A | 2021-06-29 |
| 39 |
SonoThera
SonoThera is a biotechnology company that creates non-viral genetic therapies us…
|
San Francisco | 11 - 50 | $60.8M | Series A | 2022-12-05 |
| 40 |
Verge Genomics
Verge Genomics uses machine learning and human genomics to accelerate drug disco…
|
San Francisco | 11 - 50 | $134.1M | Series Unknown | 2023-07-01 |
| 41 |
Opus Genetics
Opus Genetics develops therapies for inherited retinal diseases and other ophtha…
|
Raleigh | 11 - 50 | $22.7M | Grant | 2025-06-23 |
| 42 |
Medilink Therapeutics
Medilink Therapeutics is a biotech company focusing on next-generation antibody-…
|
Suzhou | 51 - 100 | $120.0M | Series B | 2022-03-14 |
| 43 |
Bionexus Gene Lab
BioNexus Gene Lab Corp does non-invasive blood- based dynamic genome screening a…
|
Kuala Lumpur | 11 - 50 | $505.0M | Post Ipo Equity | 2025-12-02 |
| 44 |
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat deva…
|
Boston | 101 - 250 | $301.6M | Post Ipo Equity | 2024-06-24 |
| 45 |
Marea Therapeutics
Marea is a biotechnology company that develops therapies and medications for the…
|
San Francisco | 11 - 50 | $255.4M | Series B | 2024-06-18 |
| 46 |
Ascidian Therapeutics
Ascidian Therapeutics is a biotechnology company that focuses on medical and cli…
|
Boston | 11 - 50 | $90.0M | Series A | 2023-11-08 |
| 47 |
Prenetics
Prenetics is a genetic and diagnostic health testing company that helps to ident…
|
Hong Kong | 251 - 500 | $235.7M | Post Ipo Equity | 2025-10-27 |
| 48 |
Singlera Genomics
Singlera Genomics is a fast growing company focusing on non-invasive genetic tes…
|
La Jolla | 101 - 250 | $274.9M | Series B | 2022-06-08 |
| 49 |
Cofactor Genomics
Cofactor Genomics builds multidimensional models of disease to deliver true prec…
|
San Francisco | 11 - 50 | $29.0M | Series Unknown | 2025-12-15 |
| 50 |
Inocras
Inocras provides AI-driven genomic analysis focused on cancer and rare diseases.
|
San Diego | 51 - 100 | $52.7M | Series Unknown | 2024-12-05 |